<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>19(3)</volume><submitter>Sanchez-Garcia A</submitter><funding>no funding associated with the work</funding><pubmed_abstract>The bacille Calmette-Guérin (BCG) vaccine is administered in many countries as part of their vaccination schedules. Epidemiologic studies have suggested a possible benefit of this vaccine in the context of the COVID-19 pandemic and other respiratory infections. We aimed to assess the safety of this intervention in BCG-primed adults. Adult health care workers (&lt;i>n&lt;/i> = 451) received a single intradermal application of the BCG vaccine (Tokyo 172 strain) in the deltoid region of the right arm. Follow-up (30 days) calls and clinical inspections were guided using a standardized data sheet to assess local and systemic reactions. Early local reactions were common at 24 h and 7 days, such as erythema (74.9%, 69.2%), induration (55.7%, 59%), a papule (53.4%, 47.7%), and edema (48.3%, 38.1). Local</pubmed_abstract><journal>Human vaccines &amp; immunotherapeutics</journal><pagination>2271760</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10653682</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The safety of BCG revaccination in the context of COVID-19.</pubmed_title><pmcid>PMC10653682</pmcid><pubmed_authors>Rodriguez-Gutierrez R</pubmed_authors><pubmed_authors>Gonzalez-Gonzalez JG</pubmed_authors><pubmed_authors>Tamez-Guerra R</pubmed_authors><pubmed_authors>Sanchez-Garcia A</pubmed_authors><pubmed_authors>Barrera FJ</pubmed_authors><pubmed_authors>Gonzalez-Saldivar G</pubmed_authors><pubmed_authors>Ramirez-Garcia LA</pubmed_authors></additional><is_claimable>false</is_claimable><name>The safety of BCG revaccination in the context of COVID-19.</name><description>The bacille Calmette-Guérin (BCG) vaccine is administered in many countries as part of their vaccination schedules. Epidemiologic studies have suggested a possible benefit of this vaccine in the context of the COVID-19 pandemic and other respiratory infections. We aimed to assess the safety of this intervention in BCG-primed adults. Adult health care workers (&lt;i>n&lt;/i> = 451) received a single intradermal application of the BCG vaccine (Tokyo 172 strain) in the deltoid region of the right arm. Follow-up (30 days) calls and clinical inspections were guided using a standardized data sheet to assess local and systemic reactions. Early local reactions were common at 24 h and 7 days, such as erythema (74.9%, 69.2%), induration (55.7%, 59%), a papule (53.4%, 47.7%), and edema (48.3%, 38.1). Local</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Dec</publication><modification>2025-04-04T03:20:29.73Z</modification><creation>2025-04-04T03:20:29.73Z</creation></dates><accession>S-EPMC10653682</accession><cross_references><pubmed>37936434</pubmed><doi>10.1080/21645515.2023.2271760</doi></cross_references></HashMap>